Printer Friendly
The Free Library
14,680,088 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

New devices may ease use of Copaxone and Betaseron.


The FDA FDA
abbr.
Food and Drug Administration


FDA,
n.pr See Food and Drug Administration.

FDA,
n.pr the abbreviation for the Food and Drug Administration.
 recently approved the Copaxone autoject and the Mixject vial vial

a small bottle.
 adapters, to help people using Copaxone (glatiramer acetate glatiramer acetate (glahtear´a-meer as´tāt),
n a medication used to decrease or stop a relapse of multiple sclerosis.
 for injection) self-administer the drug. The autoject steadies the syringe and hides the needle from view. Mixject vial adapters allow for the use of the same syringe for both mixing and injecting. (Copaxone must be diluted with sterile water before using.)

Teva Marion Partners, the manufacturer of Copaxone, is giving the autoject away free to people with a doctor's prescription for Copaxone. The device can also be obtained by contacting Teva's Shared Solutions at 1-800-867-2444 or online at <www.copaxone.com>.

Autoject 2 for use with Betaseron

The Betaseron Foundation provides Autoject 2 devices, made by Owen Mumford, free to qualifying patients for use with Betaseron (interferon beta-1b interferon beta-1b

Betaferon (UK), Betaseron

Pharmacologic class: Biological response modifier

Therapeutic class: Antiviral, immunoregulator

Pregnancy risk category C

Action

). This is similar to the Copaxone device. Tracy Bradey of the Betaseron Foundation said that people currently receiving Betaseron through the Foundation are automatically eligible to receive one and should contact the Foundation at 1-800-948-5777, or online at <www.betaseron.org>. Others should call MS Pathways at 1-800-788-1467 for more information.

A needle-less option.

Some people are exploring the needle-free Biojector 2000, made by Bioject Medical Technologies Inc. The Biojector 2000 uses a CO2 cartridge to deliver doses of medication through the skin. This product has not been FDA approved for use with any of the disease-modifying MS drugs, although Dr. Stanley van den Noort, of the University of California The University of California has a combined student body of more than 191,000 students, over 1,340,000 living alumni, and a combined systemwide and campus endowment of just over $7.3 billion (8th largest in the United States).  Department of Neurology neurology (nrŏl`əjē, ny–), study of the morphology, physiology, and pathology of the human nervous system. , said that he had "no problem" with its use with either Copaxone or Betaseron. Avonex, which is taken via the muscle, "cannot be judged," Dr. van den Noort said. The cost may not be covered by insurance, he noted.

Anyone interested in the injection-easing devices currently on the market should discuss them with their physician.
COPYRIGHT 2001 National Multiple Sclerosis Society
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Inside MS
Geographic Code:1USA
Date:Mar 22, 2001
Words:295
Previous Article:From the passenger seat. (Driving And MS).(multiple sclerosis)
Next Article:ORCCAMIND researches alternative and complementary therapies in neurology. (News).(Oregon Center for Complementary and Alternative Medicine in...
Topics:



Related Articles
Treatment options - now there are three. (for multiple sclerosis)(includes related information)
MS news at the American Academy of Neurology meeting.
Avonex and Copaxone?
A versus B versus C versus no treatment: A longed-for study offers cloudy results.(Avonex, Betaseron, and Copaxone for treatment of multple sclerosis)
Accessing the abcs.(Avonex, Betaseron, and Copaxone access for care of multiple sclerosis)
Coral study testing Copaxone by mouth.
Heads up! Has your health plan cut back on MS drug coverage? (National MS Society News).(multiple sclerosis)
FDA approves Rebif. (News).(Brief Article)(Product Announcement)
FDA approves room-temperature Betaseron. (News).(Brief Article)(Product Announcement)
Rebif [in context].

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles